News
BHC
5.17
+1.17%
0.06
Bausch Health signs letter of intent with pan-Canadian Pharmaceutical Alliance for public coverage of OKEDI schizophrenia drug
PUBT · 19h ago
Bausch Health Canada, pCPA sign LOI on public drug plan coverage for PrOKEDI schizophrenia treatment
PUBT · 19h ago
Bausch Health, Canada, Completes Negotiations With pan-Canadian Pharmaceutical Alliance Resulting In LOI For PrOKEDI 75mg And 100mg, Long-Acting Injectable Antipsychotic Agent For Schizophrenia Treatment
Benzinga · 21h ago
BAUSCH HEALTH, CANADA INC. AND THE PAN-CANADIAN PHARMACEUTICAL ALLIANCE SIGN LETTER OF INTENT FOR PUBLIC DRUG PLAN COVERAGE OF (PR)OKEDI® (RISPERIDONE FOR EXTENDED-RELEASE INJECTABLE SUSPENSION) FOR THE TREATMENT OF SCHIZOPHRENIA
Reuters · 21h ago
Weekly Report: what happened at BHC last week (0601-0605)?
Weekly Report · 1d ago
UPDATE 2-Cooper Companies beats quarterly estimates on strong contact lenses demand
Reuters · 5d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Abivax SA Sponsored ADR (ABVX), Bausch Health Companies (BHC) and Healthequity (HQY)
TipRanks · 06/03 08:10
Bausch Health Companies Enters Oversold Territory (BHC)
NASDAQ · 06/02 20:29
Bausch Health: Invest In The Short-Term Bonds, Not The Stock
Seeking Alpha · 06/02 16:13
Weekly Report: what happened at BHC last week (0525-0529)?
Weekly Report · 06/01 10:31
Bausch Health And Solta Medical Announce Thermage Awarded AAA Well-Known Trademark Certification By China Trademark Association
Benzinga · 05/28 20:43
Bausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China
Barchart · 05/28 15:15
Weekly Report: what happened at BHC last week (0518-0522)?
Weekly Report · 05/25 10:35
AllianceBernstein Global High Income Fund publishes report; NAV USD 11.37
PUBT · 05/22 20:06
Bausch + Lomb joins Goldman Sachs Global Healthcare Conference fireside chat
PUBT · 05/21 11:15
Bausch Health director Frank D. Lee disposes 24,456 common shares worth $132,794.08
PUBT · 05/20 21:42
Bausch Health director Eiry Roberts files initial beneficial ownership statement
PUBT · 05/20 21:16
Bausch + Lomb shareholders elected directors at annual meeting
PUBT · 05/20 20:33
Better Futures raises EUR 600,000 from Enterprise Ireland, angel investors
PUBT · 05/20 11:40
Bausch Health elects Eiry Roberts to board, names her science and technology chair
PUBT · 05/19 20:19
More
Webull provides a variety of real-time BHC stock news. You can receive the latest news about Bausch Health Companies Inc through multiple platforms. This information may help you make smarter investment decisions.
About BHC
Bausch Health Companies Inc. is a global, diversified pharmaceutical company. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.